
Hormone receptor positive (HR+), HER2-negative (HER2-) tumors represent approximately 70% of metastatic breast cancer (mBC) patients. Endocrine treatment (ET) in combination with cyclin-dependent kinase 4-6 inhibitors (CDK4/6i) is the standard of care in first line, and an effective treatment option in second and subsequent lines.
Like
Save
Share